PRESS RELEASE | Basel, Switzerland, January 5, 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that it will be attending Biotech Showcase: The Investor Conference for Innovators on the 10-12 January 2022. The Versameb team will be attending virtually.

PRESS RELEASE | Basel, Switzerland, November 4, 2021

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at the 9th International mRNA Health Conference taking place on 9th and 10th November 2021 in Berlin.

PRESS RELEASE | Basel, Switzerland, October 4, 2021

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces its participation in the  21st Annual Biotech in Europe Forum organized by SACHS Associates taking place virtually 7th-8th October 2021.

PRESS RELEASE | Basel, Switzerland, March 11, 2021

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces that its management team will be presenting at / attending the following virtual conferences.

PRESS RELEASE | Basel, Switzerland, January 8, 2021

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces the appointment of Dr Klaas Zuideveld as Chief Executive Officer (CEO). Prof Friedrich Metzger will move back to the role of Chief Scientific Officer (CSO) to focus on developing Versameb’s innovative VERSagile RNA platform to enhance and combine therapeutic protein expression and cellular targeting, optimizing and tailoring first-in-class RNA therapeutics for hard to treat diseases.